Lantern Pharma Inc. (NASDAQ: LTRN) experienced a 3.5% increase in premarket trading on Tuesday following the release of extended survival data from an ongoing Phase 2 lung cancer study.
The HARMONIC trial data relate to patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who received up to six cycles of LP-300 in combination with carboplatin and pemetrexed. Lantern reported that this group reached a median progression-free survival (PFS) of 8.9 months, compared with 8.4 months overall within the L858R cohort of 15 patients.
More than 70% of evaluable patients in the L858R subgroup experienced measurable tumor shrinkage. Lantern noted that several patients demonstrated responses that were durable, persisting beyond two years in select cases. The L858R cohort produced a 77% clinical benefit rate.
The company has formalized the updated dataset and accompanying presentation slides in a Form 8-K filing and indicated it will present the findings during partnering meetings at the American Society of Clinical Oncology (ASCO) 2026 meeting in Chicago.
Lantern's chief executive highlighted the signal emerging from the biomarker-defined population while emphasizing the safety profile. "What we are seeing is an early signal that strengthens the longer the biomarker specific patients remain on therapy, and very importantly no notable changes in the exceptionally clean safety and tolerability profile for LP-300," said Panna Sharma, CEO & President of Lantern Pharma.
On tolerability, the company reported that LP-300 added no clinically meaningful toxicity beyond the expected effects of the carboplatin/pemetrexed backbone across 31 patients treated. In cross-trial comparisons cited by Lantern, the LP-300 plus chemotherapy regimen compared favorably with the FDA-approved amivantamab-plus-chemotherapy, particularly in terms of administration burden and dermatologic toxicities.
Regulatory progress was also noted: the U.S. Food and Drug Administration cleared a protocol amendment permitting extension of LP-300 dosing from a previous maximum of six cycles to up to eight cycles. Lantern additionally stated that the L858R subgroup comprises approximately 40% of EGFR-mutated patients globally, according to the company.
Context and market response
The release of the extended PFS figure and associated tolerability information coincided with the premarket uptick in Lantern's shares. The company is using the updated materials to support partnering conversations at a major oncology conference, signaling a near-term strategic focus on collaboration rather than immediate commercialization.
Takeaway
The HARMONIC trial updates provide an incremental efficacy signal and reinforce the company’s safety claims for LP-300 in a biomarker-defined subgroup. Lantern has taken steps to document the data publicly and to seek partners based on the updated results and the FDA-cleared protocol amendment.